Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Gastric Cancer(ALTER0503)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ALTER0503
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 27 Dec 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
- 27 Dec 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 19 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.